Arcturus Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology company focused on mRNA therapeutics and vaccines with a cash position expected to last into Q1 of 2027, the analyst tells investors in a research note. The firm says that for each of the company’s lead programs, Arcturus recently initiated Phase 2 studies powered to provide significant proof of concept in patients with data expected in the first half of 2025. BTIG sees these catalysts as the major reason to own the stock now. On the vaccine front, the Arcturus platform leverages the attractive properties of self-amplifying mRNA, the analyst adds.